Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
377
datasets available to search
ShareScore release 0.9.0
Dataset results
377 results for “GLP-1”
Dataset: Roundhill Glp-1 & Weight Loss ETF (OZEM) Stock Performance
This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
ClinicalTrials.gov study NCT02787551. IPD Sharing: YES. Countries: 9. Publications: 5.
GLP-1 Increases pre-ingestive satiation via hypothalamic circuits in mice and humans
<p>GLP-1 receptor agonists (GLP-1RAs) are effective anti-obesity drugs. However, the precise central mechanisms of GLP-1RAs remain elusive. We administered GLP-1RAs to obese patients and observed heightened sense of pre-ingestive satiation. Analysis of human and mouse brain samples pinpointed GLP-1R neurons in the dorsomedial hypothalamus (DMH) as candidates for encoding pre-ingestive satiation. Optogenetic manipulation of DMH<sup>GLP-1R</sup> neurons caused satiation. Calcium imaging demonstrated that these neurons are actively involved in encoding pre-ingestive satiation. GLP-1RA administration increased the activity of DMH<sup>GLP-1R</sup> neurons selectively during eating behavior. We further identified an intricate interplay between DMH<sup>GLP-1R</sup> neurons and arcuate NPY/AgRP neurons (ARC<sup>NPY/AgRP</sup>), to regulate food intake. Our findings reveal a hypothalamic mechanism through which GLP-1RAs control pre-ingestive satiation, offering novel neural targets for obesity and metabolic diseases.</p>
"Structural and Functional Diversity among Agonist-Bound States of the GLP-1 Receptor" - MD trajectories
<p>Topology (.psf) and coordinates (.xtc) files of:</p> <p>- Ex4 WT, D-Ala Ex4, and L-Ala Ex4 (all simulated in water - without receptor)</p> <p>- Partial unbinding and binding simulations of Ex4 WT, D-Ala Ex4 and L-Ala Ex4 from GLP-1R </p> <p>Water molecules, lipids, and ions have been removed.</p> <p> </p>
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
ClinicalTrials.gov study NCT00707031. IPD Sharing: Not stated. Countries: 18. Publications: 2.
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Mid
ClinicalTrials.gov study NCT05671653. IPD Sharing: NO. Countries: 1. Publications: 0.
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
ClinicalTrials.gov study NCT02589626. IPD Sharing: Not stated. Countries: 1. Publications: 1.
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
ClinicalTrials.gov study NCT00886626. IPD Sharing: Not stated. Countries: 1. Publications: 1.
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
ClinicalTrials.gov study NCT00712673. IPD Sharing: Not stated. Countries: 16. Publications: 4.
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
ClinicalTrials.gov study NCT01232946. IPD Sharing: NO. Countries: 1. Publications: 1.
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
ClinicalTrials.gov study NCT00763815. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
ClinicalTrials.gov study NCT02738151. IPD Sharing: Not stated. Countries: 16. Publications: 1.
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
ClinicalTrials.gov study NCT01800968. IPD Sharing: Not stated. Countries: 1. Publications: 4.
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
ClinicalTrials.gov study NCT00715624. IPD Sharing: Not stated. Countries: 15. Publications: 4.
Effect of Supplement on Appetite and GLP-1
ClinicalTrials.gov study NCT06790771. IPD Sharing: YES. Countries: 1. Publications: 11.
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
ClinicalTrials.gov study NCT00866658. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients
ClinicalTrials.gov study NCT07229170. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
ClinicalTrials.gov study NCT00688701. IPD Sharing: Not stated. Countries: 12. Publications: 2.
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
ClinicalTrials.gov study NCT00713830. IPD Sharing: Not stated. Countries: 16. Publications: 4.
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
ClinicalTrials.gov study NCT01847313. IPD Sharing: Not stated. Countries: 1. Publications: 25.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.